Osborne Clarke Advises Tiger Global On Its Lead Investment In Lifebit's £44M Series B Round


Bristol-based lawyers at international legal practice Osborne Clarke have advised investment firm Tiger Global Management on its lead investment in Lifebit Biotech’s £44.3 million Series B funding round.

Lifebit Biotech is the global leader in population genomics and precision medicine software. The round is joined by existing investors Eurazeo IDinvest Partners, Pentech Ventures and Beacon Capital.

The past year has seen Lifebit acquire numerous high-profile clients across the public and private sectors, including a recent contract to support the implementation of the Hong Kong Genome Project, the first large-scale genome sequencing initiative in Hong Kong and a long-term AI-partnership with German pharma giant Boehringer Ingelheim.

Osborne Clarke provided English law advice to Tiger Global. The Osborne Clarke team was led by US managing partner Steve Wilson, Bristol-based associate director James Taylor and associate Andrew Massey. US law advice was provided by Gunderson Dettmer.

Osborne Clarke’s international venture capital practice is widely recognised as a leading European law firm for companies operating in tech-enabled industries and in the life science and healthcare sector. The Venture Capital team is ranked tier one by The Legal 500 and has experts across London, the Thames Valley and Bristol.